SEARCH

SEARCH BY CITATION

References

  • 1
    Aurora V,Winter JN. Current controversies in follicular lymphoma. Blood Rev. 2006; 20: 179-200.
  • 2
    Meijerink JP. t(14;18), a journey to eternity. Leukemia. 1997; 11: 2175-2187.
  • 3
    Gallagher CJ,Gregory WM,Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4: 1470-1480.
  • 4
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 9: 669-687.
  • 5
    Sacchi S,Marcheselli L,Bari L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007; 109: 2077-2082.
  • 6
    Czuczman MS,Weaver R,Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22: 4711-4716.
  • 7
    Sacchi S,Pozzi S,Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007; 110: 121-128.
  • 8
    Demann W,Kneba M,Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732.
  • 9
    van Oers MH,Klasa R,Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006 108: 3295-3301.
  • 10
    Forstpointner R,Dreyling M,Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 3064-3071.
  • 11
    McLaughlin P,Rodriguez MA,Hagemeister FB, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND (fludarabine, mitoxantrone, dexamethasone) chemotherapy and rituximab monoclonal antibody therapy, with interferon maintenance [abstract]. J Clin Oncol. 2003; 22: 564. Abstract 2269.
  • 12
    Herold M,Pasold R,Srock S, et al. Result of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL) [abstract]. Blood. 2004; 104: 169a. Abstract 584.
  • 13
    Marcus R,Imrie K,Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 1417-1423.
  • 14
    Kaplan EL,Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
  • 15
    Mantel N,Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748.
  • 16
    Cox D. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-202.
  • 17
    Armitage P,Berry G. Statistical Method in Medical Research. 2nd ed. Oxford, UK: Blackwell Scientific Publications; 1987.
  • 18
    Solal-Celigny P,Roy P,Colombat P, et al. Follicular lymphoma prognostic index. Blood. 2004; 104: 1258-1265.
  • 19
    Rambaldi A,Lazzari M,Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002; 99: 856-862.
  • 20
    Rambaldi A,Carlotti E,Oldani E, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005; 9: 3428-3433.